AJP - Renal Fuel your research with LabChart
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Am J Physiol Renal Physiol 258: F1237-F1244, 1990;
0363-6127/90 $5.00
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hutchison, F. N.
Right arrow Articles by Martin, V. I.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hutchison, F. N.
Right arrow Articles by Martin, V. I.

AJP - Renal Physiology, Vol 258, Issue 5 1237-F1244, Copyright © 1990 by American Physiological Society

ARTICLES

Effects of modulation of renal kallikrein-kinin system in the nephrotic syndrome

F. N. Hutchison and V. I. Martin
Department of Medicine, Veterans Administration Medical Center, Martinez 94553.

Albuminuria (UAlbV) can be reduced by converting-enzyme inhibitors (CEI), but the hormonal mechanism responsible for this effect has not previously been defined. Since CEI increase kinin activity as well as reduce angiotensin II (ANG II) activity, experiments were performed to determine the effect of isolated alterations in kinin and ANG II metabolism on UAlbV in rats with passive Heymann pephritis. Phosphoramidon was used to potentiate kinin activity without altering ANG II synthesis. Aprotinin was utilized in combination with the CEI, enalapril, to prevent the increase in kinin activity caused by CEI. UAlbV and the fractional renal clearance of albumin (FCAlb) decreased significantly after either phosphoramidon or enalapril, although only enalapril reduced blood pressure. Glomerular filtration rate (GFR) was not affected by either drug. Phosphoramidon did not affect plasma renin activity (PRA) or the pressor response to angiotensin I (ANG I), indicating that ANG II synthesis was not altered. Aprotinin prevented the reduction in UAlbV and FCAlb produced by CEI but not the hypotension, elevated PRA, or ANG I pressor blockade produced by CEI. Aprotinin alone had no effect on UAlbV, GFR, PRA, or blood pressure. UAlbV can be reduced by increasing kinin activity by a mechanism that is not dependent on suppression of ANG II activity or reduction in GFR or blood pressure. CEI may reduce proteinuria as a result of their action on the kallikrein-kinin system rather than on the renin-angiotensin system.


This article has been cited by other articles:


Home page
 J. Am. Soc. Nephrol.Home page
M. J. ZYCHMA, J. GUMPRECHT, E. ZUKOWSKA-SZCZECHOWSKA, and W. GRZESZCZAK
Polymorphisms in the Genes Encoding for Human Kinin Receptors and the Risk of End-Stage Renal Failure: Results of Transmission/DisequilibriumTest
J. Am. Soc. Nephrol., October 1, 1999; 10(10): 2120 - 2124.
[Abstract] [Full Text]

Home page
 Am. J. Physiol. Renal Physiol.Home page
A. Remuzzi, N. Perico, F. Sangalli, G. Vendramin, M. Moriggi, P. Ruggenenti, and G. Remuzzi
ACE inhibition and ANG II receptor blockade improve glomerular size-selectivity in IgA nephropathy
Am J Physiol Renal Physiol, March 1, 1999; 276(3): F457 - F466.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online